Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel Alone or in Combination With Enzalutamide as First-line Treatment for Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone: a Single Center, Randomized, Open-label Study

NCT05627752 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT05627752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05627752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel Alone or in Combination With Enzalutamide as First-line Treatment for Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone: a Single Center, Randomized, Open-label Study
Lead sponsor
Zhongnan Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 1, 2024
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, prostate cancer